Daniel J Lightell1, Stephanie C Moss2, T Cooper Woods3. 1. Department of Physiology and the Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA; Laboratory of Molecular Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA. 2. Laboratory of Molecular Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA. 3. Department of Physiology and the Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA; Laboratory of Molecular Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA. Electronic address: twoods3@tulane.edu.
Abstract
BACKGROUND AND AIMS: Diabetes is associated with accelerated arterial intimal thickening that contributes to the increased cardiovascular disease seen in this population. In healthy arteries, intimal thickening is inhibited by elevated levels of the cyclin-dependent kinase inhibitor, p27Kip1, and intimal thickening is promoted by activation of the mammalian Target of Rapamycin to promote degradation of p27Kip1 protein. Recently, we reported that two microRNAs, miR-221 and -222, which promote intimal thickening via down-regulation of mRNA encoding p27Kip1, are elevated in the arteries of diabetic patients. To determine if these miRNAs are critical to the increased intimal thickening under diabetic conditions, we examined the regulation of p27Kip1in a mouse model of diabetes. METHODS: Comparisons of p27Kip1 signaling in NONcNZO10 mice fed a diabetogenic versus control diet were performed using immunochemistry and real-time PCR. RESULTS: Vascular smooth muscle cells and arteries of diabetic mice exhibited decreased levels of p27Kip1 that derived from destabilization of p27Kip1 mRNA in an extracellular signal response kinase-1/2 (ERK-1/2) dependent manner. The activity of ERK-1/2 is increased in the arteries of diabetic mice and promotes an increase in miR-221 and -222. Inhibition of miR-221 and -222 restores normal levels of p27Kip1 mRNA and protein in the arteries of diabetic mice and reduces intimal thickening following wire injury. CONCLUSIONS: These data suggest diabetes is accompanied by increases in arterial miR-221 and -222 expression that promotes intimal thickening. Inhibition of the increased miR-221 and -222 may be efficacious in the prevention of the cardiovascular complications of diabetes.
BACKGROUND AND AIMS: Diabetes is associated with accelerated arterial intimal thickening that contributes to the increased cardiovascular disease seen in this population. In healthy arteries, intimal thickening is inhibited by elevated levels of the cyclin-dependent kinase inhibitor, p27Kip1, and intimal thickening is promoted by activation of the mammalian Target of Rapamycin to promote degradation of p27Kip1 protein. Recently, we reported that two microRNAs, miR-221 and -222, which promote intimal thickening via down-regulation of mRNA encoding p27Kip1, are elevated in the arteries of diabeticpatients. To determine if these miRNAs are critical to the increased intimal thickening under diabetic conditions, we examined the regulation of p27Kip1in a mouse model of diabetes. METHODS: Comparisons of p27Kip1 signaling in NONcNZO10 mice fed a diabetogenic versus control diet were performed using immunochemistry and real-time PCR. RESULTS: Vascular smooth muscle cells and arteries of diabeticmice exhibited decreased levels of p27Kip1 that derived from destabilization of p27Kip1 mRNA in an extracellular signal response kinase-1/2 (ERK-1/2) dependent manner. The activity of ERK-1/2 is increased in the arteries of diabeticmice and promotes an increase in miR-221 and -222. Inhibition of miR-221 and -222 restores normal levels of p27Kip1 mRNA and protein in the arteries of diabeticmice and reduces intimal thickening following wire injury. CONCLUSIONS: These data suggest diabetes is accompanied by increases in arterial miR-221 and -222 expression that promotes intimal thickening. Inhibition of the increased miR-221 and -222 may be efficacious in the prevention of the cardiovascular complications of diabetes.
Authors: Donald E Cutlip; Amit G Chhabra; Donald S Baim; Manish S Chauhan; Sachin Marulkar; Joseph Massaro; Ameet Bakhai; David J Cohen; Richard E Kuntz; Kalon K L Ho Journal: Circulation Date: 2004-08-30 Impact factor: 29.690
Authors: P L Faries; D I Rohan; H Takahara; M C Wyers; M A Contreras; W C Quist; G L King; F W Logerfo Journal: J Vasc Surg Date: 2001-03 Impact factor: 4.268
Authors: R Gallo; A Padurean; T Jayaraman; S Marx; M Roque; S Adelman; J Chesebro; J Fallon; V Fuster; A Marks; J J Badimon Journal: Circulation Date: 1999-04-27 Impact factor: 29.690
Authors: Y Izumi; S Kim; M Namba; H Yasumoto; H Miyazaki; M Hoshiga; Y Kaneda; R Morishita; Y Zhan; H Iwao Journal: Circ Res Date: 2001-06-08 Impact factor: 17.367
Authors: Robert C Fang; Zol B Kryger; Donald W Buck; Mauricio De la Garza; Robert D Galiano; Thomas A Mustoe Journal: Wound Repair Regen Date: 2010-10-18 Impact factor: 3.617
Authors: R Kornowski; G S Mintz; K M Kent; A D Pichard; L F Satler; T A Bucher; M K Hong; J J Popma; M B Leon Journal: Circulation Date: 1997-03-18 Impact factor: 29.690
Authors: A R Folsom; J H Eckfeldt; S Weitzman; J Ma; L E Chambless; R W Barnes; K B Cram; R G Hutchinson Journal: Stroke Date: 1994-01 Impact factor: 7.914
Authors: Chasity B Coleman; Daniel J Lightell; Stephanie C Moss; Michael Bates; Patrick E Parrino; T Cooper Woods Journal: Mol Cell Endocrinol Date: 2013-05-03 Impact factor: 4.102
Authors: Thomas A Sorrentino; Phat Duong; Laura Bouchareychas; Mian Chen; Allen Chung; Melinda S Schaller; Adam Oskowitz; Robert L Raffai; Michael S Conte Journal: JVS Vasc Sci Date: 2020-02-28